American University of Beirut, Beirut, Lebanon.
Novartis Gene Therapies, Inc., Bannockburn, IL, USA.
Gene Ther. 2024 Jan;31(1-2):1-11. doi: 10.1038/s41434-023-00425-x. Epub 2023 Oct 30.
In the rapidly evolving landscape of biotechnologies, cell and gene therapies are being developed and adopted at an unprecedented pace. However, their access and adoption remain limited, particularly in low- and middle-income countries (LMICs). This study aims to address this critical gap by exploring the potential of applying a hub and spoke model for cell and gene therapy delivery in LMICs. We establish the identity and roles of relevant stakeholders, propose a hub and spoke model for cell and gene therapy delivery, and simulate its application in Brazil and the Middle East and North Africa. The development and simulation of this model were informed by a comprehensive review of academic articles, grey literature, relevant websites, and publicly available data sets. The proposed hub and spoke model is expected to expand availability of and access to cell and gene therapy in LMICs and presents a comprehensive framework for the roles of core stakeholders, laying the groundwork for more equitable access to these lifesaving therapies. More research is needed to explore the practical adoption and implications of this model.
在生物技术快速发展的背景下,细胞和基因疗法正在以前所未有的速度得到开发和采用。然而,它们的可及性和采用仍然受到限制,特别是在低收入和中等收入国家(LMICs)。本研究旨在通过探索在 LMICs 中应用中心辐射模型来解决这一关键差距,为细胞和基因治疗的提供提供可能性。我们确定了相关利益相关者的身份和角色,提出了一种用于细胞和基因治疗提供的中心辐射模型,并在巴西和中东及北非进行了模拟应用。该模型的开发和模拟是通过对学术文章、灰色文献、相关网站和公开数据集的全面审查得到的。预期所提出的中心辐射模型将扩大细胞和基因治疗在 LMICs 中的可及性和可及性,并为核心利益相关者的角色提供一个全面的框架,为获得这些救命疗法奠定更公平的基础。需要进一步研究以探讨该模型的实际采用和影响。